

# Elpro International Ltd

17th Floor, Nirmal, Nariman Point  
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000  
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

April 15, 2024

To,  
BSE Limited  
Phiroze Jeejeebhoy  
Towers Dalal Street  
Mumbai - 400 001

Dear Sir / Ma'am,

**Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")**

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited ("the Company") has acquired equity shares of "Thyrocare Technologies Limited".

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Part A of Schedule III of the SEBI Listing Regulations, is attached as "**Annexure A**".

This is for your information and record.

Thanking you,

For **Elpro International Limited**

**Rushabh  
Rajen Ajmera** Digitally signed by  
Rushabh Rajen Ajmera  
Date: 2024.04.15  
18:17:57 +05'30'

**Rushabh Ajmera**  
**Company Secretary**

Encl. as above

# Elpro International Ltd

17th Floor, Nirmal, Nariman Point  
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000  
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

## Annexure A

Sr. No.	Particulars	Details								
1.	Name of the target entity, details in brief such as size, turnover etc.:	<b>Name of the target entity:</b> Thyrocare Technologies Limited  <b>Consolidated Turnover as per last audited financials (FY 2022-23):</b> <table border="1"><thead><tr><th>Particulars</th><th>Amount (in crores)</th></tr></thead><tbody><tr><td>Revenue from operations</td><td>526.67</td></tr><tr><td>Other income</td><td>8.42</td></tr><tr><td><b>Total</b></td><td><b>535.09</b></td></tr></tbody></table>	Particulars	Amount (in crores)	Revenue from operations	526.67	Other income	8.42	<b>Total</b>	<b>535.09</b>
Particulars	Amount (in crores)									
Revenue from operations	526.67									
Other income	8.42									
<b>Total</b>	<b>535.09</b>									
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”:	No								
3.	Industry to which the entity being acquired belongs:	Healthcare Service Provider								
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	Investment Purpose								
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	N.A.								
6.	Indicative time period for completion of the acquisition:	N.A.								
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash Consideration								
8.	Cost of acquisition or the price at which the shares are acquired:	INR 5.53 Crores								

# Elpro International Ltd

17th Floor, Nirmal, Nariman Point  
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000  
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

9.	Percentage of shareholding / control acquired and/or number of shares acquired:	Fresh Acquisition: 89,435 Equity Shares  (Previous Holding: 39,983 Equity Shares) (Total Holding with Fresh Acquisition: 1,29,418 Equity Shares)																			
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p><b>Brief Background:</b></p> <p>Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.</p> <p>Thyrocare operates with a Central Processing Laboratory (CPL) in Mumbai - India for esoteric tests; and Regional Processing Laboratory in major metro cities of India. They have focused on strong technologies, strong brands and strong systems that enable their clients the best of science and technology at an affordable cost.</p> <p><b>Line of Business:</b></p> <p>Healthcare Services</p> <p><b>Website of the entity:</b></p> <p><a href="http://www.thyrocare.com">www.thyrocare.com</a></p> <p><b>Date of Incorporation:</b></p> <p>January 28, 2000</p> <p><b>Consolidated Turnover of last 3 Financial Years:</b></p> <table border="1" data-bbox="776 1430 1474 1688"><thead><tr><th rowspan="2">Particulars</th><th colspan="3">Amount (in crores)</th></tr><tr><th>FY 2022-23</th><th>FY 2021-22</th><th>FY 2020-21</th></tr></thead><tbody><tr><td>Revenue from operations</td><td>526.67</td><td>588.86</td><td>494.62</td></tr><tr><td>Other income</td><td>8.42</td><td>29.25</td><td>12.43</td></tr><tr><td><b>Total</b></td><td><b>535.09</b></td><td><b>618.11</b></td><td><b>507.05</b></td></tr></tbody></table> <p><b>Country in which the target has presence:</b></p> <p>India</p>	Particulars	Amount (in crores)			FY 2022-23	FY 2021-22	FY 2020-21	Revenue from operations	526.67	588.86	494.62	Other income	8.42	29.25	12.43	<b>Total</b>	<b>535.09</b>	<b>618.11</b>	<b>507.05</b>
Particulars	Amount (in crores)																				
	FY 2022-23	FY 2021-22	FY 2020-21																		
Revenue from operations	526.67	588.86	494.62																		
Other income	8.42	29.25	12.43																		
<b>Total</b>	<b>535.09</b>	<b>618.11</b>	<b>507.05</b>																		